Trimetazidine as a modifier of doxorubicin+cyclophosphamideinduced hyperdyslipidemia

Aim. The present work aimed at studying the proatherogenic potential of doxorubicin-cyclophosphamide (AC) chemotherapy regimen while simultaneously substantiating use trimetazidine as a modifier changes induced. Material and Methods. fundamental, randomized, controlled, experimental in vivo study was conducted. To perform work, 80 inbred Wistar rats were randomly divided into four groups with equal numbers animals each group. course dosages doxorubicin, cyclophosphamide, 15, 150, 42 mg/kg, respectively. experiment lasted for 14 days. Trimetazidine chosen probable stabilizer endothelial functioning. Results. deviations following parameters evaluated framework this study: total cholesterol, triglycerides, high-density lipoproteins, low-density lipoproteins. Coronary index atherogenic (CA) also analyzed prognostic indicators. Statistically significant intergroup differences recorded lipid profiles (one-way ANOVA, p < 0.0001) two weeks after beginning AC regimen. It is worthy note that caused destabilization all studied cholesterol metabolism showed statistically pathogenetically mild hypolipidemic effect. concentration CA group 2 higher by 187.4 172.8%, values coronary risk (CRI) 115.8 113.9% than corresponding 1 4, Comparative analysis 3 TMZ associated decreases 55.5% CRI 44.2% (Tukey’s post-hoc test, 0.05). Conclusions. (1) an inducer hyperdyslipidemia, (2) had